NCT06010888View on ClinicalTrials.gov

Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC

PHASE2RecruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

March 31, 2026

Conditions
Colorectal Cancer
Interventions
DRUG

Fruquintinib+mFOLFOX6/FOLFIRI

Fruquintinib: 4mg po qd, d1-d21, q4w with mFOLFOX6/FOLFIRI (standard)

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER